Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. May 7, 2020; 26(17): 2097-2110
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2097
Table 1 Patient characteristics
MELD 6-11 (n = 25)MELD ≥ 17 (n = 25)P value
Age, yr (IQR)62 (56-69)58 (56-66)0.58
Male sex, n (%)12 (48)16 (64)0.39
BMI (SD)26 (6)27 (6)0.43
MELD score (IQR)8 (7-10)22 (19-24)< 0.0001
Primary disease, n (%)0.20
NASH2 (8)4 (16)
Nutritive toxic15 (60)9 (36)
Hepatitis B2 (8)2 (8)
Hepatitis C5 (20)4 (16)
Other1 (4)6 (24)
Listed for LT, n (%)2 (8)5 (20)0.41
Renal replacement therapy, n (%)0 (0)2 (8)0.49
Anticoagulants, n (%)9 (36)11 (44)0.77
P2Y12–receptor inhibitor1 (4)0 (0)
ASA5 (20)8 (32)
LMWH3 (12)3 (12)
Laboratory parameters
Bilirubin, mg/dL (SD)0.9 (0.5)5.7 (4.4)< 0.0001
Creatinine, mg/dL (SD)0.8 (0.19)1.9 (1.5)< 0.0001
Urea, mg/dL (SD)28.7 (9.6)58.8 (41.6)< 0.001
INR1.1 (0.1)1.7 (0.6)< 0.0001
aPTT, s (SD)30 (3.7)35 (7.5)0.047
Fibrinogen, mg/dL (SD)275 (51)209 (90)0.006
Platelet count, 103/µL (SD)145 (51)138 (49)0.60
Minimum, 103/µL8072
Maximum, 103/µL275274
Thrombocytopenia < 150 × 103/µL, n (%)16 (64)18 (72)1.00
Table 2 Results of impedance aggregometric and thrombelastometric assays
All patientsMELD 6-11MELD ≥ 17P value
Impedance aggregometry
AUCADP1, U (IQR)43 (30-56)45 (30-56)42 (29-67)0.80
AUCADP1< 55 U, n (%)34 (68)17 (68)17 (68)0.58
AUC ASPI2, U (IQR)71 (57-99)72 (57-96)68 (43-104)0.53
AUCASPI2 < 79 U, n (%)22 (44)12 (48)10 (40)0.94
AUCTRAP, U (IQR)92 (61-106)94 (80-109)79 (60-110)0.26
AUCTRAP < 92 U, n (%)24 (48)9 (36)15 (60)0.09
Thrombelastometry
EXTEM
CT, s (IQR)71 (65-79)70 (65-77)73 (64-81)0.52
CT < 42 s, n (%)1 (2)01 (4)0.10
CT > 74 s, n (%)19 (38)8 (32)11 (44)0.38
CFT, s (IQR)100 (75-115)103 (82-109)97 (67-132)0.96
CFT < 46 s, n (%)1 (2)0 (0)1 (4)0.10
CFT > 148 s, n (%)6 (12)1 (4)5 (20)0.18
MCF, mm (IQR)57 (51-63)58 (53-63)52 (46-63)0.06
MCF <49mm, n (%)10 (20)0 (0)10 (40)< 0.001
MCF >71mm, n (%)4 (8)2 (8)2 (8)1.00
α-angle, ° (IQR)73 (69-77)74 (70-76)71 (66-80)0.31
α-angle < 63°, n (%)3 (6)0 (0)3 (12)0.23
α-angle > 81°, n (%)4 (8)1 (4)3 (12)0.60
INTEM
CT, s (IQR)197 (183-226)195 (181-217)202 (185-230)0.80
CT < 137 s, n (%)0 (0)0 (0)0 (0)a
CT > 246 s, n (%)9 (18)4 (16)4 (16)1.00
CFT, s (IQR)92 (69-110)91 (80-109)91 (62-120)0.55
CFT < 40 s, n (%)1 (2)0 (0)1 (4)1.00
CFT > 100 s, n (%)22 (44)8 (32)11 (44)0.56
MCF, mm (IQR)54 (48-59)55 (51-59)52 (42-59)0.16
MCF < 52 mm, n (%)20 (40)8 (32)11 (44)0.38
MCF > 72 mm, n (%)1 (2)0 (0)1 (4)1.00
α-angle, °(IQR)73 (69-76)71 (67-75)74 (69-80)0.55
α-angle < 71°, n (%)19 (38)10 (40)9 (36)0.77
α-angle > 82°, n (%)0 (0)0 (0)0 (0)a
FIBTEM
CT, s (IQR)63 (56-71)59 (55-65)68 (59-79)0.004
CT < 43 s, n (%)0 (0)0 (0)0 (0)a
CT > 69 s, n (%)3 (6)4 (16)9 (36)0.19
MCF, mm (IQR)17 (12-20)17 (14-20)12 (9-21)0.11
MCF < 9 mm, n (%)4 (8)0 (0)4 (16)0.11
MCF > 25 mm, n (%)3 (6)0 (0)3 (12)0.23